Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of “Moderate Buy” by Analysts

Posted by on Jun 25th, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has received an average rating of “Moderate Buy” from the fifteen brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $139.80.

A number of brokerages recently commented on MIRM. HC Wainwright restated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Citizens Jmp upped their target price on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research note on Monday, June 15th. TD Cowen upped their target price on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wolfe Research assumed coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 target price for the company. Finally, Evercore reaffirmed an “outperform” rating and set a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th.

Read Our Latest Stock Report on MIRM

Insider Activity

In other news, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $93.82, for a total transaction of $469,100.00. Following the sale, the chief financial officer owned 44,788 shares in the company, valued at approximately $4,202,010.16. This trade represents a 10.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 37,594 shares of company stock worth $3,608,758. Corporate insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $1,478,000. TD Asset Management Inc bought a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $1,129,000. William Blair Investment Management LLC bought a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $22,965,000. Nan Fung Trinity HK Ltd. lifted its holdings in Mirum Pharmaceuticals by 45.6% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock valued at $17,969,000 after purchasing an additional 71,214 shares during the last quarter. Finally, SBI Okasan Asset Management Co.Ltd. bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $1,283,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $114.77 on Thursday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The firm has a market capitalization of $7.00 billion, a price-to-earnings ratio of -8.43 and a beta of 0.50. The company’s fifty day moving average is $99.56 and its two-hundred day moving average is $93.23. Mirum Pharmaceuticals has a 52-week low of $47.89 and a 52-week high of $115.87.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.30) earnings per share. Equities research analysts forecast that Mirum Pharmaceuticals will post -2.01 EPS for the current year.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

Featured Stories

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.